Advisor Group Holdings, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Advisor Group Holdings, Inc.

$39.8 Billion
Q4 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,695 shares of APLS stock, worth $40,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,695

Previous 2,114 19.82%

Holding current value

$40,917

Previous $60,000 10.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	SELL	$26.18 - $35.42 $10,969 - $14,840	-419 Reduced 19.82%	1,695 $54,000
Q3 2024 Nov 13, 2024	SELL	$28.84 - $41.15 $4,556 - $6,501	-158 Reduced 6.95%	2,114 $60,000
Q2 2024 Aug 13, 2024	SELL	$38.07 - $59.71 $27,753 - $43,528	-729 Reduced 24.29%	2,272 $87,000
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $165,616 - $216,685	-2,990 Reduced 49.91%	3,001 $176,000
Q4 2023 Feb 12, 2024	SELL	$37.14 - $64.82 $2,228 - $3,889	-60 Reduced 0.99%	5,991 $358,000
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $25,589 - $96,536	1,082 Added 21.78%	6,051 $230,000
Q2 2023 Aug 10, 2023	SELL	$76.68 - $93.31 $710,670 - $864,797	-9,268 Reduced 65.1%	4,969 $452,000
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $511,930 - $735,756	10,988 Added 338.2%	14,237 $939,000
Q4 2022 Feb 10, 2023	BUY	$43.24 - $61.04 $9,037 - $12,757	209 Added 6.88%	3,249 $168,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $16,695 - $25,983	373 Added 13.99%	3,040 $209,000
Q2 2022 Aug 10, 2022	BUY	$35.07 - $59.21 $2,174 - $3,671	62 Added 2.38%	2,667 $120,000
Q1 2022 May 04, 2022	SELL	$35.46 - $54.12 $49,502 - $75,551	-1,396 Reduced 34.89%	2,605 $132,000
Q3 2021 Nov 05, 2021	BUY	$31.4 - $69.84 $56,143 - $124,873	1,788 Added 80.8%	4,001 $132,000
Q2 2021 Aug 02, 2021	BUY	$40.9 - $64.9 $286 - $454	7 Added 0.32%	2,213 $139,000
Q1 2021 May 13, 2021	SELL	$40.8 - $57.39 $3,671 - $5,165	-90 Reduced 3.92%	2,206 $95,000
Q4 2020 Feb 10, 2021	SELL	$30.79 - $57.2 $3,079 - $5,720	-100 Reduced 4.17%	2,296 $131,000
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $3,968 - $6,158	-160 Reduced 6.26%	2,396 $78,000
Q1 2020 May 18, 2020	BUY	$17.91 - $44.33 $45,777 - $113,307	2,556 New	2,556 $68,000

Others Institutions Holding APLS

# of Institutions

302

Shares Held

123M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.65B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Apellis Pharmaceuticals, Inc. Transaction History